Human adaptive immune receptors recognizing inactivated poliovirus type 1 capsid antigens (PV1-BCR/TCR)

Human adaptive immune receptors recognizing inactivated poliovirus type 1 (IPV1) capsid antigens are the specific B-cell receptors (BCRs) and T-cell receptors (TCRs) that mediate the body's defense against type 1 poliovirus. These receptors identify specific epitopes on the viral capsid proteins VP1, VP2, and VP3, which are preserved in the inactivated (Salk) vaccine (Minor, 1992). When the inactivated virus is administered, BCRs on B lymphocytes bind to these antigens, triggering a signaling cascade that leads to the production of neutralizing antibodies (Salk & Salk, 1977). These antibodies are critical for preventing the virus from binding to the human poliovirus receptor (CD155) on host cells, thereby neutralizing the infection before it can reach the central nervous system (Mendelsohn et al., 1989). TCRs complement this process by recognizing viral peptides presented by major histocompatibility complex (MHC) molecules, facilitating the maturation of the B-cell response and the establishment of long-term immunological memory (Plotkin et al., 2018). The interaction between vaccine antigens and these receptors is the fundamental mechanism for global polio eradication efforts, and clinical monitoring of this target's activation is typically performed through serum neutralization assays to ensure protective immunity (Hogle et al., 1985).

Other names

Poliovirus type 1 specific antibodiesAnti-PV1 B-cell receptorsAnti-PV1 T-cell receptorsType 1 poliovirus neutralizing antibody receptors

The inactivated poliovirus type 1 antigens act as ligands for these receptors, stimulating B-cell differentiation into plasma cells that secrete neutralizing antibodies and T-cell activation for cellular immunity and memory.